drugset
drugset / Trial / NCT05794672

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects

NCT05794672 ↗

Phase 1 Terminated 30 enrolled AstraZeneca Parexel · collab
NaParallel-groupSingle-blindTreatment

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of elarekibep after single and multiple doses given twice daily (BID) by inhalation or intravenous (IV) in healthy Japanese subjects compared with placebo.

Timeline

Start
2023-04-11
Primary completion
2023-07-08
Completion
2023-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Elarekibep Protein / enzyme biologic — Inhaled

Indications

No indication recorded.